Metsera Announces Topline Results from Phase 1 Trial of MET-233i

Summary

On June 9, 2025, Metsera, Inc. announced the topline results from its Phase 1 clinical trial of MET-233i, a subcutaneously injectable ultra-long acting amylin analog for the treatment of obesity and overweight. The trial, which included a single ascending dose (SAD) and a five-week multiple ascending dose (MAD) portion, demonstrated dose-dependent weight loss across all cohorts. MET-233i was generally well-tolerated, with the most common treatment-emergent adverse events being gastrointestinal-related and mild in severity. The Company plans to advance MET-233i in ongoing monotherapy and co-administration trials.